Your browser doesn't support javascript.
loading
Level and timing of product substitution in a trial of e-cigarettes for smokers not interested in quitting.
Sargent, James D; Pratt, Sarah I; Brunette, Mary F; Ferron, Joelle C; Santos, Meghan M; Stoolmiller, Mike.
Afiliação
  • Sargent JD; Department of Pediatrics, Geisel School of Medicine, Dartmouth College, Hanover, United States.
  • Pratt SI; Department of Biomedical Data Sciences, Geisel School of Medicine, Dartmouth College, Hanover, United States.
  • Brunette MF; Department of Psychiatry, Dartmouth Hitchcock Medical Center, Lebanon, United States.
  • Ferron JC; Department of Psychiatry, Dartmouth Hitchcock Medical Center, Lebanon, United States.
  • Santos MM; Department of Psychiatry, Dartmouth Hitchcock Medical Center, Lebanon, United States.
  • Stoolmiller M; Department of Psychiatry, Dartmouth Hitchcock Medical Center, Lebanon, United States.
Tob Induc Dis ; 222024.
Article em En | MEDLINE | ID: mdl-38873183
ABSTRACT

INTRODUCTION:

The e-cigarette market is large and diverse. Traditional smoking cessation trials involving a control group and a 6-month observation period are an inefficient methodology for testing the multiple treatment options e-cigarettes provide for harm reduction in cigarette smokers. We determined when product substitution occurred in the e-cigarette provision arm of an e-cigarette substitution trial for cigarette smokers who were not interested in quitting.

METHODS:

We conducted a secondary analysis of 120 cigarette smokers with severe mental illness (recruitment 2017-2020) who were given disposable e-cigarettes for 8 weeks and assessed at weeks 0 (t0), 2, 4, 6, and 8. We explored product substitution through visit-to-visit correlations in change in product use, then developed a dual process growth model for cigarette and e-cigarette use to test the association between increases in e-cigarette use and concurrent decreases in cigarettes smoked.

RESULTS:

Mean age of the participants was 45.9 years, and 42.7% smoked ≥20 cigarettes per day. Almost all product substitution occurred between t0 and t2. For the average smoker (18 cigarettes per day), t2 cigarette frequency decreased by 0.39 (95% CI -0.56 - -0.22) cigarettes for each additional e-cigarette session. There was effect modification (p=0.033), such that baseline light smokers (<10 cigarettes/day) had no significant decrease in t2 cigarette frequency, regardless of their initial increase in e-cigarette use, while heavy smokers (38 cigarettes/day) switched products nearly on a one-to-one basis.

CONCLUSIONS:

In this study, most product substitution occurred early, and heavier smokers had larger t2 decreases in cigarettes/day with increased e-cigarette use. If confirmed with replication studies, the findings could suggest establishment of a novel outcome for e-cigarette studies - early product substitution - and support the value of short-term comparative effectiveness trials that compare multiple potentially lower harm tobacco products. CLINICAL TRIAL REGISTRATION The study was registered on the official website of ClinicalTrials.gov. IDENTIFIER ID NCT03050853.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article